Avances en el tratamiento de la infección por el virus de la inmunodeficiencia humana

Referencias bibliográficas

• •Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral de adultos infectados por el virus de la inmunodeficiencia humana (enero 2010). Disponible en: www.gesida.seimc.org.
• •Guidelines for the use of antirretroviral agents in HIV-1-infected adults and adolescents, December 1, 2009. Disponible en: www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf
• •European AIDS Clinical Society. European guidelines for clinical management and treatment of HIV infected adults in Europe. Disponible en: www.europeanaidsclinicalsociety.org/guidelines.asp.
• •M.A. Thompson, J.A. Aberg, P. Cahn, J.S.G. Montaner, G. Rizzardini, and A. Telenti Antiretroviral treatment of adult HIV infection: 2010. Recommendations of the International AIDS Society USA Panel JAMA 3 2010 321 333
• •J.V. Baker, G. Peng, J. Rapkin, D.I. Abrams, M.J. Silverberg, and R.D. MacArthur CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection AIDS 22 2008 841 848
• •A. Monforte, D. Abrams, C. Pradier, R. Weber, P. Reiss, and F. Bonnet Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies AIDS 22 2008 2143 2153
• •Antiretroviral Therapy Cohort Collaboration Causes of death in HIV-1- infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies Clin Infect Dis 50 2010 1387 1396
• •W.M. El-Sadr, J.D. Lundgren, J.D. Neaton, F. Gordin, D. Abrams, and R.C. Arduino CD4+ count-guided interruption of antiretroviral treatment N Engl J Med 355 2006 2283 2296
• •M.M. Kitahata, S.J. Gange, A.G. Abraham, B. Merriman, M.S. Saag, A.C. Justice NAACCORD Investigators Effect of early versus deferred antiretroviral therapy for HIV on survival N Engl J Med 360 2009 1815 1826
• •HIV-CAUSAL Collaboration The effect of combined antiretroviral therapy on the overall mortality of HIV infected individuals AIDS 24 2010 123 137
• •Polo R, Iribarren JA, de José MI, Muñoz Gálligo E, coordinadores. Recomendaciones de la Secretaría del Plan Nacional sobre el Sida, el Grupo de estudio de Sida, la Sociedad Española de Ginecología y Obstetricia y la Asociación Española de Pediatría para el seguimiento de la infección por el VIH con relación a la reproducción, el embarazo y la prevención de la transmisión vertical (diciembre 2007). Disponible en: http://www.gesida.seimc.org/
• •S. Attia, M. Egger, M. Muller, M. Zwahlen, and N. Low Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis AIDS 23 2009 1397 1404
• •V. Soriano, M. Puoti, M. Peters, Y. Benhamou, M. Sulkowski, and F. Zoulim Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel AIDS 22 2008 1399 1410
• •J.A. Pineda, J.A. García-García, M. Aguilar-Guisado, M.J. Rios-Villegas, J. Ruiz-Morales, and A. Rivero Clinical progression of hepatitis C virusrelated chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy Hepatology 46 2007 622 630
• •E.J. Schwartz, L.A. Szczech, M.J. Ross, M.E. Klotman, J.A. Winston, and P.E. Klotman Highly active antirretroviral therapy and the epidemic of HIV+ endstage renal disease J Am Soc Nephrol 16 2005 2412 2420
• •The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group Response to combination antiretroviral therapy: variation by age AIDS 22 2008 1463 1473
• •V.A. Triant, J.B. Meigs, and S.K. Grinspoon Association of C reactive protein and HIV infection with acute myocardial infarction J Acquir Immune Defic Syndr 51 2009 268 273
• •S. Mallal, E. Phillips, G. Carosi, J.M. Molina, C. Workman, and J. Tomazic HLA-B*5701 screening for hypersensitivity to abacavir N Engl J Med 358 2008 568 579
• •A. Hill, and W. Sawyer Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5,168 patients HIV Med 10 2009 527 535
• •P.E. Sax, C. Tierney, A.C. Collier, M.A. Fischl, K. Mollan, and L. Peeples Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy N Engl J Med 361 2009 2230 2240
• •S.A. Riddler, R.H. Haubrich, A.G. DiRienzo, L. Peeples, W.G. Powderly, K.L. Klingman AIDS Clinical Trials Group Study A5142 Team Class-sparing regimens for initial treatment of HIV-1 infection N Engl J Med 358 2008 2095 2106
• •J. Molina, J. Andrade-Villanueva, J. Echeverria CASTLE Study Team Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96 week efficacy and safety results of the CASTLE study JAIDS 53 2010 323 332
• •A.M. Mills, M. Nelson, D. Jayaweera, K. Ruxrungtham, I. Cassetti, and P.M. Girard Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis AIDS 23 2009 1679 1688
• •Lennox J, DeJesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. JAIDS. En prensa 2010.
• •M. Müller, S. Wandel, R. Colebunders, S. Attia, H. Furrer, M. Egger IeDEA Southern and Central Africa Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis Lancet Infect Dis 10 2010 251 261
• •G. Fatkenheuer, M. Nelson, A. Lazzarin, I. Konourina, A.I.M. Hoepelman, and H. Lampiris Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection N Engl J Med 359 2008 1442 1455
• •M. Nelson, K. Arasteh, B. Clotet, D.A. Cooper, K. Henry, and C. Katlama Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials J Acquir Immune Defic Syndr 40 2005 404 412
• •C. Katlama, R. Haubrich, J. Lalezari, A. Lazzarin, J.V. Madruga, J.M. Molina DUET-1, DUET-2 study groups Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials AIDS 23 2009 2289 2300
• •R.T. Steigbigel, D.A. Cooper, P.N. Kumar, J.E. Eron, M. Schechter, and M. Markowitz Raltegravir with optimized background therapy for resistant HIV-1 infection N Engl J Med 359 2008 339 354
• •C.B. Hicks, P. Cahn, D.A. Cooper, S.L. Walmsley, C. Katlama, and B. Clotet Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials Lancet 368 2006 466 475
• •B. Clotet, N. Bellos, J.M. Molina, D. Cooper, J.C. Goffard, and A. Lazzarin Efficacy and safety of darunavir/ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials Lancet 369 2007 1169 1178 • Y. Yazdanpanah, C. Fagard, D. Descamps, A.M. Taburet, C. Colin, B. Roquebert ANRS 139 TRIO Trial Group High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatmentexperienced patients infected with multidrug-resistant HIV Clin Infect Dis 49 2009 1441 1449
• •J. Montaner, D. Guimaraes, J. Chung, Z. Gafoor, M. Salgo, and R. DeMasi Prognostic staging of extensively pretreated patients with advanced HIV-1 disease HIV Clin Trials 6 2005 281 290
• •J.R. Arribas, A. Horban, J. Gerstoft, G. Fätkenheuer, M. Nelson, and N. Clumeck The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml AIDS 24 2010 223 230
• •A. Rieger, D. Banhegyi, and W. Schmidt The MONET trial 96 week analysis: darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs, for patients with HIV RNA < 50 copies/ml at baseline XVIII International AIDS Conference (AIDS 2010) Viena, July 18-23, Abstract THLBB209 2010
• •F. Lozano de León Efectos adversos del tratamiento antirretrovírico 2006 Lippincott Williams & Wilkins Ltd Madrid
• •A. Gutiérrez-Valencia, P. Viciana, R. Palacios, R. Ruiz-Valderas, F. Lozano, and A. Terrón Sociedad Andaluza de Enfermedades Infecciosas. Stepped- dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial Ann Intern Med 151 2009 149 156
• •M.R. Nelson, C. Katlama, J.S. Montaner, D.A. Cooper, B. Gazzard, and B. Clotet The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years AIDS 21 2007 1273 1281
• •S.W. Worm, C. Sabin, R. Weber, P. Reiss, W. El-Sadr, and F. Dabis Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study J Infect Dis 201 2010 318 330
• •Drug Interactions HIV. Drug interactions charts. Disponible en: http://www.hiv-druginteractions.org/.
• •HIV InSite. Database of antiretroviral drug interactions. Disponible en: http://hivinsite.ucsf.edu/.
• •www.aidsinfo.nih.gov
• •www.europeanaidsclinicalsociety.org
• •www.gesida.seimc.org